What evidence supports the use of Zilongin 8 (Zilongjin tablets) as an adjunct to standard chemotherapy in patients with non‑small cell lung cancer?

Evidence for Zilongjin Tablets in Non-Small Cell Lung Cancer

Zilongjin tablets combined with platinum-based chemotherapy significantly improve treatment outcomes in NSCLC patients compared to chemotherapy alone, with demonstrated benefits in disease control, objective response rates, quality of life, and reduction of chemotherapy-related toxicities.

Key Evidence Supporting Use

The strongest evidence comes from a 2023 meta-analysis 1 that included 14 randomized controlled trials with 2,430 patients. This analysis demonstrated that Zilongjin tablets as an adjunct to conventional chemotherapy were significantly superior to chemotherapy alone across multiple clinically meaningful endpoints.

Efficacy Outcomes

Disease Control and Response:

• Zilongjin tablets ranked second among seven oral traditional Chinese medicines for improving objective response rate (OR = 2.62,95% CI 1.92-3.57) 2
• The combination showed significantly better disease control rates compared to chemotherapy alone 1

Quality of Life Improvements:

• Zilongjin tablets ranked among the top two interventions for improving Karnofsky performance status (OR = 3.47,95% CI 2.14-5.63) 2
• A 2016 overview of systematic reviews found Zilongjin tablet plus chemotherapy had a pooled relative risk of 3.36 (95% CI: 1.30-8.66) for quality of life improvement 3
• These QOL benefits were maintained even after adjustment for publication bias 3

Safety Profile and Toxicity Reduction

A critical advantage of Zilongjin tablets is their ability to mitigate chemotherapy-related adverse effects:

• Liver and kidney toxicity: Ranked first or second for reduction (SUCRA = 18.9%) 2
• Leukopenia: Ranked second for decreasing white blood cell suppression (SUCRA = 26.3%) 2
• Gastrointestinal toxicity: Demonstrated reduction in nausea, vomiting, and abdominal discomfort 4, 2

This toxicity-reducing effect is particularly valuable given that standard guidelines emphasize platinum-based doublet chemotherapy as the backbone of NSCLC treatment 5, 6, but these regimens carry significant toxicity burdens.

Mechanism of Action

Network pharmacology analysis identified 29 drug-disease intersecting targets, with the majority associated with inflammatory response modulation 1. The "ingredient-target-pathway" network contained 119 nodes and 429 edges, suggesting Zilongjin tablets work through multiple pathways including:

• Regulation of inflammatory responses
• Modulation of the PPAR signaling pathway via targets including JUN, FOS, PPARG, and CDH1 7
• Potential benefits extending to COVID-19-related inflammation 1

Clinical Context and Guidelines

Standard NSCLC treatment guidelines establish the foundation for where Zilongjin fits:

Current evidence-based guidelines recommend platinum-based doublet chemotherapy for stage IV NSCLC patients with performance status 0-2 5, 6. The 2019 Pan-Asian guidelines specifically endorse platinum combinations with third-generation agents (gemcitabine, vinorelbine, taxanes) for both squamous and non-squamous histologies 6.

Zilongjin tablets should be positioned as an adjunct to—not a replacement for—these standard chemotherapy regimens. The evidence consistently shows benefit only when combined with conventional chemotherapy, not as monotherapy 1, 2, 3.

Practical Implementation

Recommended approach:

1. Initiate standard platinum-based doublet chemotherapy according to histology and molecular profile
2. Add Zilongjin tablets concurrently with chemotherapy cycles
3. Continue through 4-6 cycles of chemotherapy (per standard guidelines 6)
4. Monitor for both chemotherapy efficacy and toxicity reduction

Key caveats:

• Stop use if condition worsens, symptoms persist beyond 7 days, or excessive skin irritation develops 4
• Report unexpected side effects to appropriate regulatory authorities 4
• Consult with healthcare provider before use if there are concerns 4

Limitations and Considerations

While the evidence is encouraging, several limitations warrant mention:

• Most studies are from Chinese databases and populations, potentially limiting generalizability
• The 2016 overview noted that rigorous placebo-controlled trials with proper blinding are needed to confirm effectiveness 3
• Network meta-analysis showed no significant differences in comparative effectiveness among the 11 Chinese herbal medicines studied, though Zilongjin consistently ranked in the top tier 2, 3

The evidence does not support using Zilongjin tablets in patients with:

• Targetable molecular alterations (EGFR, ALK, ROS1, KRAS) who should receive targeted therapy 8, 9
• PD-L1 high expression (≥50%) who may benefit from immunotherapy monotherapy 6
• Stage I-IIIA resectable disease in the adjuvant setting (insufficient evidence in this population)

Bottom Line

For patients with advanced NSCLC receiving platinum-based chemotherapy without actionable molecular alterations, adding Zilongjin tablets provides meaningful improvements in disease control, quality of life, and chemotherapy tolerability based on meta-analytic evidence from over 2,400 patients 1, 2. This represents a reasonable adjunctive strategy within the framework of standard guideline-directed care 5, 6.